| Field | Specification |
|---|---|
| Applications | |
| Serotype | Multiple (selectable) |
| Transgene | |
| Promoter | |
| Reporter/Tag | |
| Expression regulation | |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
shRNA Knockdown Control Vector
Constitutive expression of shRNA (control) driven by the U6 + CAG (dual) promoter, with EGFP as a reporter/tag.
Research background
This AAV is built for robust expression of a research payload in targeted cells or tissues. AAV-mediated delivery is widely used for stable transgene expression in vivo and in vitro.
Mechanism and expected readouts
Expression outcomes depend on promoter choice, cell state, delivery route, and the biology of the payload. Downstream readouts often include fluorescence imaging, histology, and functional assays matched to the encoded gene.
Expression design and interpretation
Expression is driven by the U6 + CAG (dual) promoter, which determines where and how strongly the payload is expressed in your system (dual-promoter design — U6 (Pol III) transcribes the shRNA; CAG (Pol II) drives the EGFP reporter in broad mammalian cell types). The construct's regulatory logic controls where/when the payload is active; expression is constitutive (no recombinase or inducer required). A built-in reporter/tag supports validation and localization; EGFP provides a readout for expression, morphology, and targeting validation. The encoded payload is intended to support the stated experimental function (e.g., modulation, sensing, labeling, or control). Two independent transcription units operate here: U6 is a compact RNA polymerase III promoter optimized for short, non-polyadenylated transcripts such as shRNAs, while CAG is an RNA polymerase II promoter giving strong protein-level expression of the reporter. Because the hairpin is a scramble/non-targeting control, the vector reproduces the non-specific effects of shRNA expression and AAV transduction without acting on a target gene.
Subcellular targeting elements (when present) can bias localization and should be confirmed by imaging in your preparation.
Common research applications
- Cell labeling and anatomical tracing (when paired with appropriate reporters)
- Overexpression or rescue experiments for mechanistic studies
- Tool-building workflows combining expression with physiology or behavior
Experimental considerations
- Plan expression time (often weeks in vivo) according to your tissue and readout
- Validate targeting and expression pattern in pilot experiments
- Include appropriate controls (reporter-only, inactive variants, or sham injection)
Controls and validation
Typical validation includes confirming expression pattern and level, verifying functional activity with an assay matched to the payload (e.g., imaging, electrophysiology, pharmacology, or behavior), and using appropriate negative controls.
At present, the main purification approaches for rAAV include:
- Ultracentrifugation density-gradient methods, using cesium chloride (CsCl) or iodixanol as the gradient medium;
- Chemical reagent precipitation/extraction methods, mainly using PEG, ammonium sulfate, chloroform, etc.;
- Chromatographic purification methods, primarily based on affinity and ion-exchange principles.
Depending on customers’ different application needs, we can integrate multiple methods to produce high-titer, high-purity, high-quality rAAV viral products.
Can’t find the AAV you need—or require a custom design and packaging service? We offer end-to-end support for diverse research and therapeutic needs, including vector design and cloning, AAV packaging services (serotype/capsid selection and production), QC & characterization (project-appropriate testing and documentation), and library preparation for pooled or library-style workflows (project dependent). Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
